• Company
• PARP inhibitor Zejula, which is partially covered
• by Oct 8, 2021 05:57am

• Company
• Lynparza was approved for pancreatic cancer/ prostate cancer
• by Oct 8, 2021 05:56am

• Policy
• Pfizer vaccines from Romania not transported in official box
• by Lee, Jeong-Hwan Oct 8, 2021 05:56am

• Company
• Latecomer JAKi ‘Rinvoq’ now has the most indications
• by Oct 8, 2021 05:56am

• Policy
• Expanding the submission of opinions reflecting permission
• by Lee, Tak-Sun Oct 7, 2021 05:54am

• Policy
• ’With Covid’ scheme unclear with over 5,000 cases expected
• by Lee, Jeong-Hwan Oct 7, 2021 05:53am

• Policy
• Nexviazyme has been applied for domestic permission
• by Lee, Tak-Sun Oct 7, 2021 05:53am

• Policy
• Introduction of pre-registration is difficult
• by Kim, Jung-Ju Oct 7, 2021 05:53am

• Company
• Roche and Lilly to launch RET targeted cancer drugs in Korea
• by Eo, Yun-Ho Oct 6, 2021 06:06am

• Company
• Evrysdi (PO) is differentiated due to its low price
• by Oct 6, 2021 06:06am